Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

126.20 -0.50 (-0.40%)
Streaming Delayed Price Updated: 11:38 AM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
51 52 Next >
News headline image
Better Dividend Stock: AbbVie or Viatris? ↗
These pharmaceutical companies are profitable and offer above-average dividends. 
Via The Motley Fool
News headline image
2 Unbeatable Dividend Stocks Billionaires Keep Buying in a Bear Market ↗
Some of the world's most successful investors made big bets on these dividend payers recently. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Could an Investment in AbbVie Give You $10,000 in Annual Dividend Income by Retirement? ↗
This is a stock that rewards long-term investors through continual dividend increases. 
Via The Motley Fool
News headline image
Want $10,000 in Annual Dividend Income by Retirement? Here's How Much You Should Invest in AbbVie Today. ↗
This is a stock that rewards long-term investors through continual dividend increases. 
Via The Motley Fool
News headline image
AbbVie Boosts Its Dividend: Is the Dividend King a Buy? ↗
Shares of the pharmaceutical stock have left the S&P 500 index in the dust so far this year. 
Via The Motley Fool
News headline image
2 Reasons to Buy Abbott Labs and 1 Reason to Sell ↗
The healthcare company offers growth and value. 
Via The Motley Fool
News headline image
2 Stocks Down 75% and 26% to Buy Right Now ↗
It's time to go bargain hunting. 
Via The Motley Fool
News headline image
FDA Outlines Strategy To Review Infant Formula Production Rules ↗
 
Via Benzinga
News headline image
2 Reasons to Buy AbbVie Stock and 1 Reason to Sell ↗
The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem. 
Via The Motley Fool
News headline image
Want Passive Income in 2023? Buy These Dividend Kings ↗
These stocks offer you a gift: recurrent income just for owning them. 
Via The Motley Fool
News headline image
7 No-Brainer Blue-Chip Stocks to Buy for 2023 and Beyond ↗
With so many troubles ailing the economy and the broader market, investors should focus on these no-brainer blue-chip stocks to buy. 
Via InvestorPlace
News headline image
Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today ↗
Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 1.79% on an annualized basis producing an average annual return of 12.9%. Currently, Abbott Laboratories has a... 
Via Benzinga
News headline image
Better Buy: Johnson & Johnson vs. Abbott Laboratories ↗
These two healthcare giants are among the safest stocks investors can buy right now. 
Via The Motley Fool
News headline image
3 Reasons to Buy AbbVie Stock Right Now ↗
The drugmaker has something to offer to all kinds of investors. 
Via The Motley Fool
News headline image
3 Top Healthcare Stocks Defying the Bear Market ↗
These healthcare companies haven't been slowed by macroeconomic conditions. 
Via The Motley Fool
News headline image
3 Food Processing Dividend Stocks That Could Benefit From Food Shortages Driven By Russia-Ukraine War ↗
With global supply chain shortages impacting nearly every sector of the economy in the past two years, will global food shortages worsen? As the U.S. 
Via Benzinga
News headline image
Got $1,000? 2 Bear Market Stocks to Jump On Right Now ↗
Regardless of what the market does next, these top stocks have a much longer growth trajectory ahead. 
Via The Motley Fool
News headline image
Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks ↗
Just because the stock market is going haywire doesn't mean you have to sit on the sidelines. 
Via The Motley Fool
News headline image
2 Reasons to Buy DexCom, and 1 Reason to Sell ↗
Do the potential benefits outweigh the risks? 
Via The Motley Fool
News headline image
Edwards Life Sciences Stock Disaster Could Be Your Bounty
Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report. 
Via MarketBeat
Topics Death
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches ↗
Approximately 160,000 individuals in the United States are diagnosed with polycystic kidney disease, and the global prevalence of the condition is estimated at between 4 million and 7 million people. 
Via Benzinga
News headline image
Got $5,000? Buy These 3 Dividend Kings And Hold Them Forever ↗
These healthcare companies should stay relevant for years as they continue to innovate with new products. 
Via The Motley Fool
News headline image
Is DexCom a Good Healthcare Stock to Buy Now? ↗
After rising about 50% in October, investors want to know if this stock still has any fuel in the tank. 
Via The Motley Fool
News headline image
3 Dividend-Paying Stocks to Buy in November and Hold Forever ↗
Adding these stocks to your portfolio could lead to a lifetime of passive income. 
Via The Motley Fool
News headline image
This Groundbreaking Device Just Keeps Winning for Abbott Labs ↗
Its continuous glucose monitor has proven immensely effective in helping type 2 diabetes patients. 
Via The Motley Fool
News headline image
Intuitive Surgical Stock is Both a Legacy and Next-Gen Play
It’s hard to believe that the da Vinci Surgical System developed by Intuitive Surgical (NASDAQ: ISRG) is turning 22 years old since its U.S. Food and Drug 
Via MarketBeat
Topics Economy
News headline image
NYSE: ABT Investor Notice: Deadline on October 31, 2022 in Lawsuit Against Abbott Laboratories ↗
San Diego, CA -- (SBWIRE) -- 10/31/2022 -- The Shareholders Foundation announced that a deadline is coming up on October 31, 2022 in the lawsuit filed for certain investors of Abbott Laboratories... 
Via SBWire
News headline image
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Abbott Laboratories (ABT) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
ABT MONDAY DEADLINE NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.